Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. Arix Bioscience plc
  6. News
  7. Summary
    ARIX   GB00BD045071

ARIX BIOSCIENCE PLC

(ARIX)
  Report
Delayed Quote. Delayed London Stock Exchange - 10/15 11:35:18 am
140 GBX   -0.36%
10/15Transaction in own shares
DJ
10/13Transaction in own shares
DJ
10/13TR1 : Notification of Major Shareholding -2-
DJ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Arix Bioscience participates in USD90 million Series B financing for Disc Medicine

09/02/2021 | 06:21am EDT

Arix Bioscience PLC (ARIX) Arix Bioscience participates in USD90 million Series B financing for Disc Medicine 02-Sep-2021 / 11:20 GMT/BST Dissemination of a Regulatory Announcement, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement.

-----------------------------------------------------------------------------------------------------------------------

Arix Bioscience plc

Arix participates in USD90 million Series B financing for Disc Medicine

-- Arix announces investment in a new portfolio company focused on hematology, Disc Medicine

-- Series B proceeds will enable Disc Medicine to advance its clinical programmes across multiplehematologic diseases

-- Arix Managing Director Mark Chin will join Disc Medicine's Board of Directors

-- Arix joins financing round led by OrbiMed and syndicate of leading global biotech investors

LONDON, 2 SEPTEMBER 2021: Arix Bioscience plc ("Arix" or "the Company"), a global venture capital company focused on investing in and building breakthrough biotech companies, today announced that it has invested in Disc Medicine ("Disc"), a clinical-stage company focused on developing novel therapies to treat serious and debilitating hematologic disorders. As part of the financing, Arix has committed to invest USD11 million (GBP8 million[1]). Arix's Managing Director Mark Chin will join Disc Medicine's Board of Directors.

Based in Boston, MA, Disc Medicine has built a portfolio of first-in-class therapeutic candidates with the potential to address a spectrum of hematologic diseases, ranging from severe orphan conditions to widely prevalent conditions. The financing was led by OrbiMed and included new investors Janus Henderson Investors, 5AM Ventures, Rock Springs Capital and others as well as existing shareholders Atlas Venture, Novo Holdings, Access Biotechnology. Disc Medicine will use the proceeds from the financing to advance multiple programmes in Disc's hematology pipeline into phase 2 development.

Mark Chin, Managing Director at Arix and Board Director at Disc Medicine, commented:

"Arix is delighted to participate in this financing for Disc Medicine, which is in line with our strategy of backing high potential biotech companies developing innovative treatments for serious unmet medical needs. With our strong balance sheet which has been bolstered by significant realisations, we are actively investing into the major biotech players of tomorrow. The field of hematology spans an enormous range of diseases but remains significantly underserved. Disc Medicine has built a platform around a world class management team and a pipeline of assets with compelling biology and strong validation to meet this need. I'm excited to join the board and be a part of the company's future growth and success."

John Quisel, Chief Executive Officer of Disc Medicine commented:

"This financing will fuel the next stage of our company's growth as we advance multiple programs into patient studies next year. I'm delighted to have Arix's support in this round and want to extend a warm welcome to Mark as he joins the Disc Board. I'm looking forward to working together to make an impact on the lives of patients."

[ENDS]

For more information on Arix, please contact:

Arix Bioscience plc

+44 (0)20 7290 1050

ir@arixbioscience.com

Optimum Strategic Communications

Mary Clark, Manel Mateus, Vici Rabbetts

+44 (0)20 8078 4357

optimum.arix@optimumcomms.com

About Arix Bioscience plc

Arix Bioscience plc is a global venture capital company focused on investing in and building breakthrough biotech companies around cutting-edge advances in life sciences.

We collaborate with exceptional entrepreneurs and provide the capital, expertise and global networks to help accelerate their ideas into important new treatments for patients. As a listed company, we are able to bring this exciting growth phase of our industry to a broader range of investors. www.arixbioscience.com

About Disc Medicine

Disc Medicine is a clinical-stage biopharmaceutical company that is dedicated to transforming the lives of patients with hematologic disorders. Disc is building a unique portfolio of innovative, first-in-class therapeutic candidates based on fundamental pathways of red blood cell biology. Disc is committed to building a brighter future for patients who suffer from hematologic disease, ranging from severe orphan conditions to widely prevalent diseases. For more information, please visit www.discmedicine.com.

[1] At exchange rate on 31 August 2021 (GBP/USD 1.37676)

-----------------------------------------------------------------------------------------------------------------------

ISIN:           GB00BD045071 
Category Code:  MSCM 
TIDM:           ARIX 
LEI Code:       213800OVT3AHQCXNIX43 
OAM Categories: 3.1. Additional regulated information required to be disclosed under the laws of a Member State 
Sequence No.:   121334 
EQS News ID:    1230819 
 
End of Announcement  EQS News Service 
=------------------------------------------------------------------------------------
 

Image link: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1230819&application_name=news

(END) Dow Jones Newswires

September 02, 2021 06:20 ET (10:20 GMT)

All news about ARIX BIOSCIENCE PLC
10/15Transaction in own shares
DJ
10/13Transaction in own shares
DJ
10/13TR1 : Notification of Major Shareholding -2-
DJ
10/13TR1 : Notification of Major Shareholding
DJ
10/12ARIX BIOSCIENCE : Investee Aura Biosciences Posts Interim Data from Choroidal Melanoma Dru..
MT
10/12Aura Biosciences Presents Interim Phase 2 Safety -2-
DJ
10/11Transaction in own shares
DJ
10/08Pyxis Oncology prices Nasdaq IPO - Update
DJ
10/08ARIX BIOSCIENCE : Investee Pyxis Oncology Raises $167.2 Million in US IPO
MT
10/08Pyxis Oncology prices Nasdaq IPO
DJ
More news
Financials
Sales 2021 - - -
Net income 2021 - - -
Net cash 2021 133 M 183 M 183 M
P/E ratio 2021 -
Yield 2021 -
Capitalization 174 M 239 M 239 M
EV / Sales 2021 -
EV / Sales 2022 -
Nbr of Employees 12
Free-Float 72,0%
Chart ARIX BIOSCIENCE PLC
Duration : Period :
Arix Bioscience plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ARIX BIOSCIENCE PLC
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Last Close Price 140,00 GBX
Average target price 256,00 GBX
Spread / Average Target 82,9%
EPS Revisions
Managers and Directors
Robert William Henry Lyne CEO, COO, Secretary, Director & General Counsel
Marcus Karia Group Finance Director
Peregrine D. E. M. Moncreiffe Non-Executive Chairman
Graeme Smith Chief Technology Officer
Michael William Bunbury Senior Independent Director
Sector and Competitors
1st jan.Capi. (M$)
ARIX BIOSCIENCE PLC-36.07%239
INVESTOR AB (PUBL)31.82%70 054
CK HUTCHISON HOLDINGS LIMITED-2.96%25 894
GROUPE BRUXELLES LAMBERT SA19.20%17 318
HAL TRUST31.09%15 184
AB INDUSTRIVÄRDEN (PUBL)2.33%14 066